Infliximab in therapy of inflammatory bowels diseases
DOI:
https://doi.org/10.15584/ejcem.2019.1.13Keywords:
infliximab, TNFα, ulcerative colitisAbstract
Introduction. Infliximab is a monoclonal antibody that acts against tumor necrosis factor TNF-α. The drug is used in the treatment of autoimmune diseases.
Aim. This article reviewed the efficacy and safety of infliximab for the treatment in severe ulcerative colitis. This review included studies that evaluated the clinical use of infliximab.
Material and methods. This meta-analysis was performed according to systematic literature search of three major bibliographic databases (Scopus, PubMed, and Cochran).
Results. Infliximab has been approved by the US Food and Drug Administration (FDA) as a medicine to treat Leśniowski and Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. However, further trials are required to compare other parameters of efficacy such as the clinical response with infliximab.
Conclusion. In patients suffering from Crohn’s disease or ulcerative colitis under infliximab maintenance therapy, sustained good trough levels are associated with: better response and remission rates, more mucosal healing and less loss of response.
Downloads
References
Motaghi E, Ghasemi-Pirbaluti M, Zabihi M. Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: a systematic review and indirect comparison. Pharmacol Res. 2018; pii: S1043-6618(18)31146-0.
Metcalfe C, Dougall T, Bird C, Rigsby P, Behr-Gross ME, Wadhwa M. The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity. Mabs. 2018:1-13. doi: 10.1080/19420862.2018.1532766.
Mansournia MA, Rafatpanah H, Zeraati H. Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study. Ther Clin Risk Manag. 2018;14:1943-195.
Rousset L, de Masson A, Begon E, Villani A, Battistella M, Rybojad M, Jachiet M, Bagot M, Bouaziz JD, Lepelletier C. Tumor necrosis factor-alpha inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: a multicenter retrospective study. J Am Acad Dermatol. 2018. pii: S0190-9622(18)32735-X.
Song M, Li F, Xie X, Chen J, Tang M, Tian J, Du J, Ge Y, Li S, Xu S. Association of short-term efficacy for infliximab in rheumatoid arthritis with plasma concentration and anti-drug antibody. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018;43(9):982-98.
Yazici Y, Xie L, Ogbomo A, Ellis LA, Goyal K, Teeple A, Mutlu EA, Simsek I. A descriptive analysis of real-world treatment patterns of innovator (Remicade®) and biosimilar infliximab in an infliximab-naïve Turkish population. Biologics. 2018;12:97-106
van Langenberg DR, Vasudevan A. Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Aliment Pharmacol Ther. 2018;48(9):1028-1029.
Orfanoudaki E, Drygiannakis I, Koutroubakis IE. Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator? Aliment Pharmacol Ther. 2018 Nov;48(9):1037-1038.
Dreesen E, Gils A. Letter: overcoming secondary loss of response to infliximab-it is not the drug, it is how you use it! Authors' reply. Aliment Pharmacol Ther. 2018;48(9):1029-1030.
French B, Mandell K, Martinez R. Diagnosis and Treatment of Invasive Aspergillus fumigatus Wound Infection Following Subtotal Colectomy for Perforated Toxic Megacolon in an Immunosuppressed Patient. Wounds. 2018;30(10):E102-E104.
Quinn CS, Jorgenson MR, Descourouez JL, Muth BL, Astor BC, Mandelbrot DA. Management of Tumor Necrosis Factor α Inhibitor Therapy After Renal Transplantation: A Comparative Analysis and Associated Outcomes. Ann Pharmacother. 2018;1060028018802814.
Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, Geraci M, Zali MR. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterol J. 2018; 6(7):1074-1081.
Nagatomo Y, Muneuchi J, Nakashima Y, Nanishi E, Shirozu H, Watanabe M, Uike K, Nagata H, Hirata Y, Yamamura K, Takahashi Y, Okada S, Suzuki Y, Hasegawa S, Ohga S. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease. Int J Cardiol. 2018; 15;271:317-321.
Tan I, Malinzak M, Salama AKS. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy. J Immunother Cancer. 2018;6(1):77.
Oliveira RA, Fierro IM. New strategies for patenting biological medicines used in rheumatoid arthritis treatment. Expert Opin Ther Pat. 2018;28(8):635-646.
Gils A. Inflammatory Bowel Diseases at an Affordable Cost. Dig Dis. 2017;35(1-2):61-68.
Teixeira FV, Sassaki LY, Saad-Hossne R, Baima JP, Magro DO, Coy CSR, Kotze PG. Serum infliximab measurement in inflammatory bowel disease patients in remission: a comparative analysis of two different methods in a multicentric brazilian cohort. Arq Gastroenterol. 2018;55(2):192-197.
Ehsani AH, Mortazavi H, Balighi K, Hosseini MS, Azizpour A, Hejazi SP, Goodarzi A, Darvari SB. Changes in Body Mass Index and Lipid Profile in Psoriatic Patients After Treatment With Standard Protocol of Infliximab. Acta Med Iran. 2016 Sep;54(9):570-575.
Danese S, Bonovas S, Peyrin-Biroulet L. Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):22-31.
Ruiz-Villaverde R, Sánchez-Cano D, Perez-Lopez I, Aneiros-Fernández J. Metastatic Crohn Disease. Actas Dermosifiliogr. 2017;108(2):171-172.
Mudduluru BM, Shah S, Shamah S, Swaminath A. TNF-alpha antagonist induced lupus on three different agents. Postgrad Med. 2017;129(2):304-306.
Afonso J, Lopes S, Gonçalves R, Caldeira P, Lago P, Tavares de Sousa H, Ramos J, Gonçalves AR, Ministro P, Rosa I, Vieira AI, Dias CC, Magro F; Portuguese IBD Study Group (GEDII). Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016;44(7):684-92
Włodarczyk M, Fichna J, Sobolewska-Włodarczyk A. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases. Pharmacol Rep. 2016;68(4):797-80
Merras-Salmio L, Kolho KL Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2017;64(2):272-278.
Miyoshi F, Honne K, Minota S, Okada M, Ogawa N, Mimura T. A novel method predicting clinical response using only background clinical data in RA patients before treatment with infliximab. Mod Rheumatol. 2016;26(6):813-816
Saketkoo LA, Baughman RP. Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol. 2016;12(8):817-25
Galvao TF, Zimmermann IR, da Mota LM, Silva MT, Pereira MG. Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2016;35(7):1659-68
Thiebault H, Boyard-Lasselin P, Guignant C, Guillaume N, Wacrenier A, Sabbagh C, Rebibo L, Brazier F, Meynier J, Nguyen-Khac E, Dupas JL, Goëb V, Fumery M. Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab. Eur J Gastroenterol Hepatol. 2016;28(8):876-81
Singh S, Sharma D, Suri D, Gupta A, Rawat A, Rohit MK. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S134-8
Yamauchi PS, Bissonnette R, Teixeira HD, Valdecantos WC. Systematic review of efficacy of anti-tumor necrosis factor (TNF) therapy in patients with psoriasis previously treated with a different anti-TNF agent. J Am Acad Dermatol. 2016;75(3):612-618.e6
Sano H, Deguchi I, Fukuoka T, Hayashi T, Uchino A, Adachi J, Yasuda M, Takao M, Tanahashi N. Intractable Neurosarcoidosis Effectively Treated with Infliximab. Intern Med. 2016;55(7):811-4.
Kitayama N, Otsuka A, Kaku Y, Endo Y, Fujisawa A, Fujii T, Kataoka T, Hirata M, Murota H, Kabashima K. Successful treatment with anti-TNF-alpha antibody for localised lipodystrophy. Eur J Dermatol. 2016;26(3):316-7.
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Langholff W, Sandborn WJ. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018;24(3):490-501.
Novak S, Anić B, Anić F, Cerovac M, Cikeš N. Clinical significance of autoantibodies induced by infliximab treatment: two-year follow-up after infliximab discontinuation. Acta Dermatovenerol Croat. 2011;19(3):156-60.
Kochhar R, Gupta V, Dutta U, Singh K, Kochhar R. Infliximab induced endophthalmitis in a patient of fistulizing Crohn's disease. Indian J Gastroenterol. 2011;30(5):241-2.
Fasano A, D'Agostino M, Caldarola G, Feliciani C, De Simone C. Infliximab monotherapy in neuro-Behçet's disease: four year follow-up in a long-standing case resistant to conventional therapies. J Neuroimmunol. 2011;239(1-2):105-7.
García-Castro JM, Javier-Martínez R, Cáliz-Cáliz R, García-Sánchez A. Persistent inflammation of the nasal dorsum in a patient with rheumatoid arthritis treated with infliximab. Enferm Infecc Microbiol Clin. 2012;30(1):40-43.
Keino H, Watanabe T, Taki W, Okada AA. Effect of infliximab on gene expression profiling in Behcet's disease. Invest Ophthalmol Vis Sci. 2011;52(10):7681-6.
Chohan G, Barnett Y, Gibson J, Reddel SW, Barnett MH. Langerhans cell histiocytosis with refractory central nervous system involvement responsive to infliximab. J Neurol Neurosurg Psychiatry. 2012;83(5):573-575.
Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010. J Rheumatol. 2011;38(10):2258-2263.
Mitra A, Gooi J, Darling J, Newton-Bishop JA. Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia. J Am Acad Dermatol. 2011;65(3):676-677.
Barreiro-de Acosta M, García-Bosch O, Souto R, Mañosa M, Miranda J, García-Sanchez V, Gordillo J, Chacon S, Loras C, Carpio D, Maroto N, Menchén L, Rojas-Feria M, Sierra M, Villoria A, Marin-Jimenez I; Grupo joven GETECCU. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis. 2012;18(5):812-817.
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. The New England Journal of Medicine. 1999;340(18):1398-1405.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
